Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.

Chakraborty S, Harro C, DeNearing B, Bream J, Bauers N, Dally L, Flores J, Van de Verg L, Sack DA, Walker R.

Clin Vaccine Immunol. 2016 Apr 4;23(4):315-25. doi: 10.1128/CVI.00608-15. Print 2016 Apr.

2.

A study of different buffers to maximize viability of an oral Shigella vaccine.

Chandrasekaran L, Lal M, Van De Verg LL, Venkatesan MM.

Vaccine. 2015 Nov 17;33(46):6156-60. doi: 10.1016/j.vaccine.2015.09.063. Epub 2015 Oct 1.

PMID:
26428454
3.

Combination vaccines against diarrheal diseases.

Venkatesan MM, Van de Verg LL.

Hum Vaccin Immunother. 2015;11(6):1434-48. doi: 10.4161/21645515.2014.986984. Review.

4.

Editorial commentary: a Shigella vaccine against prevalent serotypes.

Van de Verg LL, Venkatesan MM.

Clin Infect Dis. 2014 Oct;59(7):942-3. doi: 10.1093/cid/ciu471. Epub 2014 Jun 23. No abstract available.

PMID:
24958237
5.

Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.

Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, van de Verg L, Walker R, Picking WL, Pasetti MF.

J Immunol. 2014 Feb 15;192(4):1630-40. doi: 10.4049/jimmunol.1302743. Epub 2014 Jan 22.

6.

Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.

Clin Vaccine Immunol. 2014 Mar;21(3):366-82. doi: 10.1128/CVI.00683-13. Epub 2014 Jan 8.

7.

Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.

Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL.

Infect Immun. 2013 Dec;81(12):4470-7. doi: 10.1128/IAI.00859-13. Epub 2013 Sep 23.

8.

Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli.

El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, Chen WH.

Clin Vaccine Immunol. 2013 Nov;20(11):1764-70. doi: 10.1128/CVI.00464-13. Epub 2013 Sep 18. Erratum in: Clin Vaccine Immunol. 2014 Apr;21(4):602.

9.

Vaccines for enteric diseases: a meeting summary.

Steele D, Riddle M, van de Verg L, Bourgeois L.

Expert Rev Vaccines. 2012 Apr;11(4):407-9. doi: 10.1586/erv.12.9.

PMID:
22551024
10.

Enteric vaccines for pediatric use. Workshop summary.

Walker RI, Van De Verg LL, Hall RH, Schmitt CK, Woo K, Hale V.

Vaccine. 2005 Nov 16;23(46-47):5432-9. Epub 2005 Apr 2.

PMID:
16286159
11.

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, Jackson WJ, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3735-45. Epub 2005 Jul 21.

PMID:
16095766
12.
13.

Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers.

Schmidt KA, Schneider H, Lindstrom JA, Boslego JW, Warren RA, Van de Verg L, Deal CD, McClain JB, Griffiss JM.

Sex Transm Dis. 2001 Oct;28(10):555-64.

PMID:
11689753
14.

Bacteriologic and histologic features in mice after intranasal inoculation of Brucella melitensis.

Mense MG, Van De Verg LL, Bhattacharjee AK, Garrett JL, Hart JA, Lindler LE, Hadfield TL, Hoover DL.

Am J Vet Res. 2001 Mar;62(3):398-405. Erratum in: Am J Vet Res 2001 Apr;62(4):642.

PMID:
11277206
15.

Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK).

Hoover DL, Crawford RM, Van De Verg LL, Izadjoo MJ, Bhattacharjee AK, Paranavitana CM, Warren RL, Nikolich MP, Hadfield TL.

Infect Immun. 1999 Nov;67(11):5877-84.

17.

Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models.

Van De Verg LL, Hartman AB, Bhattacharjee AK, Tall BD, Yuan L, Sasala K, Hadfield TL, Zollinger WD, Hoover DL, Warren RL.

Infect Immun. 1996 Dec;64(12):5263-8.

18.

Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.

Hartman AB, Van de Verg LL, Mainhart CR, Tall BD, Smith-Gill SJ.

Clin Diagn Lab Immunol. 1996 Sep;3(5):584-9.

19.

Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection.

Van De Verg LL, Bendiuk NO, Kotloff K, Marsh MM, Ruckert JL, Puryear JL, Taylor DN, Hartman AB.

Vaccine. 1996 Aug;14(11):1062-8.

PMID:
8879103
20.

Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis.

Lindler LE, Hadfield TL, Tall BD, Snellings NJ, Rubin FA, Van De Verg LL, Hoover D, Warren RL.

Infect Immun. 1996 Jul;64(7):2490-9. Erratum in: Infect Immun 1996 Oct;64(10):4414.

21.

Deletion of purE attenuates Brucella melitensis infection in mice.

Crawford RM, Van De Verg L, Yuan L, Hadfield TL, Warren RL, Drazek ES, Houng HH, Hammack C, Sasala K, Polsinelli T, Thompson J, Hoover DL.

Infect Immun. 1996 Jun;64(6):2188-92.

22.

Sialylation lessens the infectivity of Neisseria gonorrhoeae MS11mkC.

Schneider H, Schmidt KA, Skillman DR, Van De Verg L, Warren RL, Wylie HJ, Sadoff JC, Deal CD, Cross AS.

J Infect Dis. 1996 Jun;173(6):1422-7.

PMID:
8648215
23.

Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances.

Munoz C, Baqar S, van de Verg L, Thupari J, Goldblum S, Olson JG, Taylor DN, Heresi GP, Murphy JR.

Am J Trop Med Hyg. 1995 Jul;53(1):47-54.

PMID:
7542845
24.

Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.

van de Verg LL, Mallett CP, Collins HH, Larsen T, Hammack C, Hale TL.

Infect Immun. 1995 May;63(5):1947-54.

25.

Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate, EcSf2a-2.

Taylor DN, Phillip DF, Zapor M, Trofa A, Van de Verg L, Hartman A, Bendiuk N, Newland JW, Formal SB, Sadoff JC, et al.

Vaccine. 1994 May;12(6):565-8.

PMID:
8036831
26.

Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Hartman AB, Van de Verg LL, Collins HH Jr, Tang DB, Bendiuk NO, Taylor DN, Powell CJ.

Infect Immun. 1994 Feb;62(2):412-20.

27.
28.

Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM.

Infect Immun. 1992 Jun;60(6):2218-24.

29.

Supplemental Content

Loading ...
Support Center